Intro

It's been decades since new acute medications for migraine have come to market, but the FDA recently approved gepants and ditans for the acute treatment of migraine. These two new classes of treatment hold a lot of promise for the migraine community, but what exactly are they? Listen as our host Dr. Larry Newman and Dr. Jennifer Robblee cover the science behind these acute treatments, including their potential side effects and how to find out if they are right for you.

Dr. Larry Newman is Vice Chair of the American Migraine Foundation and a neurologist at NYU Langone. Dr. Jennifer Robblee is a headache neurologist at the Barrow Neurological Institute.

Additional Resources:

• Calcitonin Gene-Related Peptide Targeted Therapy for Migraine
• The American Headache Society